Ronald Kong
0000-0002-4692-7499
28 papers found
Refreshing results…
Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma
Quantitative Systems Toxicology Modeling Informed Safe Dose Selection of Emvododstat in Acute Myeloid Leukemia Patients
LC–MS/MS methods for direct measurement of sepiapterin and tetrahydrobiopterin in human plasma and clinical applications
Absorption, Metabolism, and Excretion of14C-Emvododstat Following Repeat Daily Oral Dose Administration in Human Volunteers Using a Combination of Microtracer Radioactivity and High-Radioactivity Doses
A clinical pharmacokinetic drug-drug interaction study between dextromethorphan and emvododstat, a potent anti-SARS-CoV-2 dihydroorotate dehydrogenase inhibitor
Absorption, distribution, metabolism and excretion of 14 C-vatiquinone in rats, dogs, and human subjects
A pharmacokinetic drug–drug interaction study between rosuvastatin and emvododstat, a potent anti‐SARS‐CoV ‐2 ( COVID ‐19) DHODH (dihydroorotate dehydrogenase) inhibitor
Validation and application of volumetric absorptive microsampling (VAMS) dried blood method for phenylalanine measurement in patients with phenylketonuria
First‐in‐Human Studies of Pharmacokinetics and Safety of Utreloxastat (PTC857), a Novel 15‐Lipooxygenase Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
Absorption, distribution, metabolism and excretion of 14C-Emvododstat following a single oral dose in rats and dogs
Emvododstat, a Potent Dihydroorotate Dehydrogenase Inhibitor, Is Effective in Preclinical Models of Acute Myeloid Leukemia
In vitro metabolism, pharmacokinetics and drug interaction potentials of emvododstat, a DHODH inhibitor
Unesbulin – a Novel Anti-tubulin Cancer Therapeutic
Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent
Ataluren metabolism: Ataluren-O-1β-acyl glucuronide is a stable circulating metabolite in mouse, rat, dog and human
In vitro cytochrome P450‐ and transporter‐mediated drug interaction potential of 6β‐hydroxy‐21‐desacetyl deflazacort—A major human metabolite of deflazacort
Pharmacokinetics and Safety of PTC596, a Novel Tubulin‐Binding Agent, in Subjects With Advanced Solid Tumors
The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines
Metabolite V, an epoxide species is a minor circulating metabolite in humans following a single oral dose of deflazacort
LC–MS/MS quantification of ataluren and ataluren acyl glucuronide in human plasma/urine: application in clinical studies
Missing publications? Search for publications with a matching author name.